Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Issue 1 (15th October 2021)

• Record Type: Journal Article
• Authors: Broccoli, Alessandro; Terragna, Carolina; Nanni, Laura; Martello, Marina; Armuzzi, Silvia; Agostinelli, Claudio; Morigi, Alice; Casadei, Beatrice; Pellegrini, Cinzia; Stefoni, Vittorio; Sabattini, Elena; Argnani, Lisa; Zinzani, Pier Luigi
• Is Part Of: Hematological oncology. Volume 40:Issue 1(2022)
• Page Start: 58
• Page End: 63
• Publication Date: 2021-10-15
• Subjects: BRAF‐V600E mutation -- complete response -- droplet digital PCR -- hairy cell leukemia; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2932
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: BRAF V600E mutation is the pathogenic driver of hairy cell leukemia (HCL) found in the vast majority of cases both at onset and during recurrences. The identification of the mutated allele in blood and marrow correlates with the presence of neoplastic cells and can be considered a marker of active disease. Likewise, the absence of the mutation after treatment may indicate a state of deep response. The BRAF V600E burden was measured by droplet digital polymerase chain reaction (ddPCR) and expressed as fractional abundance in 35 HCL patients at different stages of disease (onset, relapse, complete response [CR] after treatment, long‐term remission) in peripheral blood and/or bone marrow (when available). Mean values of fractional abundance for patients at diagnosis, relapse and response, respectively, were 12.26%, 16.52% and 0.02% in peripheral blood and 23.51%, 13.96% and 0.26% in bone marrow. Four patients out of 6 evaluated at response were molecularly negative for BRAF V600E in peripheral blood. Mean fractional abundance in peripheral blood tested in 14 patients with long lasting CR was 0.05%, and 10 patients were BRAF V600E negative. These preliminary results suggest that ddPCR permits to assess the active tumor burden in HCL at different disease phases and support the hypothesis that some patients in CR qualify for a molecular CR.